Complement blockade with eculizumab for treatment of severe Coronavirus Disease 2019 in pregnancy: A case series.

ABSTRACT:

Problem

We evaluated eculizumab, a complement protein C5 inhibitor, for treatment of severe COVID-19 in pregnant and postpartum individuals.

Method of study

Protocol ECU-COV-401 (clinicaltrials.gov NCT04355494) is an open label, multicenter, Expanded Access Program (EAP), evaluating eculizumab for treatment of severe COVID-19. Participants enrolled at our center from August 2020 to February 2021. Hospitalized patients were eligible if they had severe COVID-19 with bilateral pulmonary infiltrates and oxygen requirement. Eculizumab was administered on day 1 (1200 mg IV) with additional doses if still hospitalized (1200 mg IV on Days 4 and 8; 900 mg IV on Days 15 and 22; optional doses on Days 12 and 18). The primary outcome was survival at Day 15. Secondary outcomes included s

SUBMITTER: Burwick RM 

PROVIDER: S-EPMC9347938 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature